Kimberly Barone Baden leads the firm's birth defect litigation, representing hundreds of children who were born with congenital birth defects allegedly caused by antidepressants, including Zoloft®, Prozac® and Wellbutrin®; the smoking cessation drug, Zyban®; and the migraine/anti-seizure medication, Topamax®. She manages the firm's Avandia® and Crestor® litigations, as well as the Actos® bladder cancer litigation. Kimberly is also currently investigating potential claims against Sanofi-Aventis regarding the manufacturer's antiarrhythmic drug, Multaq®.
Kimberly continues to manage the firm’s nursing home abuse and neglect litigation. Representing the elderly, our nation's most defenseless population, she specifically litigates cases on behalf of both nursing home residents and assisted living facility residents who are victims of abuse and neglect nationwide. Published case: Grant v. Magnolia Manor-Greenwood, Inc., 678 S.E.2d 435 (S.C. 2009).
Additionally, Kimberly co-manages the firm's active misappropriated human remains litigation: In re New York Human Tissue Products Liability Litigation and co-managed the firm’s tainted tissue litigation in both the state and federal multidistrict litigation.
Prior to joining Motley Rice, Kimberly worked on the Fen-Phen diet drug litigation at Harrison, Kemp & Jones in Las Vegas and served as an attorney with the California District Attorney's Office in San Diego.
Kimberly is a member of the American Association for Justice, American Bar Association and South Carolina Association for Justice.
